Metoclopramide S.A.L.F.

Metoclopramide, the active ingredient in Metoclopramide S.A.L.F., is a dopamine antagonist presented as an injectable solution for intramuscular and intravenous use. It is employed to relieve nausea, vomiting and to promote gastric emptying in patients with gastroparesis. GNH USA supplies Metoclopramide S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on dopaminergic pathways to control emesis and enhance gastrointestinal motility. - Nausea and vomiting: reduces frequency and severity of acute and chronic episodes. - Post‑operative nausea and vomiting: prevents and treats nausea after surgical procedures. - Gastroparesis: improves gastric emptying and alleviates related symptoms.

Metoclopramide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: mild sedation or sleepiness. - Restlessness: feelings of inner tension or agitation. - Diarrhea: loose or frequent stools. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or rigidity. - Tardive dyskinesia: persistent, irreversible facial or limb movements. - Neuroleptic malignant syndrome: life‑threatening hyperthermia and muscle rigidity.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal or hepatic impairment: adjust monitoring as clearance may be reduced. - Elderly patients: use with caution due to increased sensitivity to central effects. - History of extrapyramidal disorders: observe closely for recurrence. - Known hypersensitivity: avoid administration if allergic reactions have occurred. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Metoclopramide can interact with several drug classes, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may increase risk of extrapyramidal reactions. - CNS depressants (e.g., opioids): additive sedation and respiratory depression. - MAO inhibitors: heightened risk of hypertensive crises.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine): altered metabolism may affect efficacy. - Antidiabetic agents: possible impact on glucose control. - Antihistamines: may enhance central nervous system side effects.